A risk prediction model of linezolid-induced thrombocytopenia for elderly patients with chronic kidney disease is urgently needed.
作者信息
Zhou Xiaohua, Ji Hongjian
机构信息
Department of Nephrology, Yancheng Third People's Hospital, Yancheng, China
School of Pharmacy, Jiangsu Vocational College of Medicine, Yancheng, China.
出版信息
Eur J Hosp Pharm. 2023 Jul;30(4):e21. doi: 10.1136/ejhpharm-2022-003370. Epub 2022 Jun 9.
Abstract
摘要
相似文献
1
A risk prediction model of linezolid-induced thrombocytopenia for elderly patients with chronic kidney disease is urgently needed.迫切需要一种针对老年慢性肾脏病患者的利奈唑胺诱导血小板减少症的风险预测模型。
Eur J Hosp Pharm. 2023 Jul;30(4):e21. doi: 10.1136/ejhpharm-2022-003370. Epub 2022 Jun 9.
2
Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.肾功能损害儿童中与利奈唑胺相关的血小板减少症
J Pediatric Infect Dis Soc. 2015 Sep;4(3):272-5. doi: 10.1093/jpids/piu035. Epub 2014 May 15.
3
High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid.接受利奈唑胺治疗的慢加急性肝衰竭患者血小板减少症的高发生率。
Hepatobiliary Pancreat Dis Int. 2015 Jun;14(3):287-92. doi: 10.1016/s1499-3872(15)60379-4.
4
Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia.建立并验证了一个包含利奈唑胺及其代谢产物 PNU142300 浓度的风险预测模型，用于预测利奈唑胺诱导的血小板减少症。
J Antimicrob Chemother. 2023 Aug 2;78(8):1974-1981. doi: 10.1093/jac/dkad191.
5
Thrombocytopenia with Tedizolid and Linezolid.替加环素和利奈唑胺相关血小板减少症。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01453-17. Print 2018 Jan.
6
Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients.开发和验证老年患者利奈唑胺诱导血小板减少症的风险预测模型。
Eur J Hosp Pharm. 2024 Feb 22;31(2):94-100. doi: 10.1136/ejhpharm-2022-003258.
7
Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice.肾功能损害患者中利奈唑胺诱导的血小板减少症：病例系列、综述及剂量建议
Drugs R D. 2024 Mar;24(1):109-115. doi: 10.1007/s40268-024-00458-6. Epub 2024 Mar 14.
8
Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.利奈唑胺在肾功能损害患者中的初始和维持剂量方案的建议。
BMC Pharmacol Toxicol. 2021 Mar 4;22(1):13. doi: 10.1186/s40360-021-00479-w.
9
A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia.一项关于利奈唑胺诱导的血小板减少症和贫血危险因素的回顾性研究。
J Infect Chemother. 2016 Aug;22(8):536-42. doi: 10.1016/j.jiac.2016.05.003. Epub 2016 Jun 16.
10
Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study.利奈唑胺所致血小板减少症增加重症监护病房患者的死亡风险：一项10年回顾性研究
J Clin Pharm Ther. 2019 Feb;44(1):84-90. doi: 10.1111/jcpt.12762. Epub 2018 Sep 22.
本文引用的文献
1
Parametric population pharmacokinetics of linezolid: A systematic review.利奈唑胺的参数群体药代动力学：系统评价。
Br J Clin Pharmacol. 2022 Sep;88(9):4043-4066. doi: 10.1111/bcp.15368. Epub 2022 May 16.
2
Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients.中国重症患者中基于谷浓度目标和肾功能的利奈唑胺给药策略
Front Pharmacol. 2022 Apr 11;13:844567. doi: 10.3389/fphar.2022.844567. eCollection 2022.
3
Development and validation of a risk prediction model for linezolid-induced thrombocytopenia in elderly patients.开发和验证老年患者利奈唑胺诱导血小板减少症的风险预测模型。
Eur J Hosp Pharm. 2024 Feb 22;31(2):94-100. doi: 10.1136/ejhpharm-2022-003258.
4
Impact of COVID-19 on Antimicrobial Consumption and Spread of Multidrug-Resistance in Bacterial Infections.2019冠状病毒病对细菌感染中抗菌药物使用及多重耐药性传播的影响
Antibiotics (Basel). 2022 Apr 18;11(4):535. doi: 10.3390/antibiotics11040535.
5
Teicoplanin-A New Use for an Old Drug in the COVID-19 Era?替考拉宁——一种老药在新冠疫情时代的新用途？
Pharmaceuticals (Basel). 2021 Nov 26;14(12):1227. doi: 10.3390/ph14121227.
6
Risk factors for linezolid-induced thrombocytopenia in adult inpatients.成年住院患者应用利奈唑胺致血小板减少的危险因素。
Int J Clin Pharm. 2022 Apr;44(2):330-338. doi: 10.1007/s11096-021-01342-y. Epub 2021 Nov 3.
7
Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis.肾功能对利奈唑胺治疗患者血小板减少症风险的影响：系统评价和荟萃分析。
Br J Clin Pharmacol. 2022 Feb;88(2):464-475. doi: 10.1111/bcp.14965. Epub 2021 Oct 10.
8
Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations.替考拉宁与治疗药物监测：不同患者人群中优化使用的最新进展。
J Infect Chemother. 2020 Sep;26(9):900-907. doi: 10.1016/j.jiac.2020.06.006. Epub 2020 Jul 2.
9
Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.抗菌药物在肿瘤中性粒细胞减少患者应用的临床实践指南：美国传染病学会 2010 年更新版。
Clin Infect Dis. 2011 Feb 15;52(4):e56-93. doi: 10.1093/cid/cir073.
Zotero 插件